



ADULT Medication Monograph

HYDROMORPHONE

This document should be read in conjunction with this [DISCLAIMER](#)



[Formulary: Restricted](#)

 **[HIGH RISK Medication](#)**

Class	Opioid Analgesic
Presentation	<p>Injection: 2mg/mL, 10mg/mL</p> <p>Tablet (Immediate Release): 2mg, 4mg, 8mg</p> <p>Tablet (Modified Release): 4mg, 8mg, 16mg, 32mg, 64mg</p> <p>Oral Liquid: 1mg/mL</p> <p>Bag: 20mg in Sodium Chloride 0.9% (100mL)</p>
Storage	<p>Injection: Store below 25°C. Protect from light. Do not refrigerate.</p> <p>Infusion Solution: Stable for 24 hours at 25°C. Protect from light.</p> <p>Tablet: Store below 25°C. Protect from light.</p> <p>Oral Liquid: Store below 25°C. Protect from light.</p>
	Schedule 8 Medication
Dose and Administration	<p>Dose: Refer relevant KEMH Clinical Guidelines for appropriate dose regimes (links below)</p> <p>Administration:</p> <p><u>IM injection:</u> Suitable. Subcutaneous injection is preferred.</p> <p><u>SUBCUT injection:</u> Suitable for injection or as a continuous subcutaneous infusion for opioid-tolerant patients with severe pain.</p> <p><u>IV injection:</u> Inject the dose over 2 to 3 minutes. If necessary, dilute the 2 mg/mL or 10 mg/mL ampoule to 10 mL with sodium chloride 0.9% to give small doses.</p> <p><u>IV infusion:</u> Suitable for patient-controlled analgesia. Check KEMH Clinical Guidelines.</p>

	<p><u>Other:</u> Suitable for intrathecal infusion - Seek specialist advice.</p> <p><u>Oral:</u> Do not cut, crush or chew slow release tablets</p>
Pregnancy	<p>1st Trimester: Considered safe to use</p> <p>2nd Trimester: Considered safe to use</p> <p>3rd Trimester: Considered safe to use</p>
Breastfeeding	Considered safe to use
Monitoring	<p>Respiratory Depression: monitor sedation score and respiratory rate.</p> <p>Constipation: always consider use with a laxative, especially if taking regularly.</p> <p>Renal impairment: Start with a low dose, titrate slowly. Monitor urea and electrolytes.</p> <p>Hepatic impairment: Reduce dose in moderate impairment. Not recommended in severe impairment.</p>
Clinical Guidelines and Policies	<p>HDWA Policies: WA Cancer and Palliative Care Network: Opioid Conversion Guide</p> <p>KEMH Clinical Guidelines: Gynaecology: Palliative Care Perioperative Services: Post-operative IV Analgesia Flowchart Gynaecology Clinical Practice Guideline: Palliative Care - Intrathecal administration of medications.</p> <p>Gynaecology Clinical Practice Guideline: Niki t34 syringe pump-continuous subcutaneous infusion management .</p> <p>KEMH Pharmaceutical & Medicines Management Guidelines: KEMH Pharmaceutical & Medicines Management Guideline: Medication Administration KEMH Pharmaceutical & Medicines Management Guideline: High Risk Medicines List KEMH Pharmaceutical & Medicines Management Guideline: Restricted Schedule 4 (S4R) and Schedule 8 (S8) Medications</p>
References	<p>The Royal Women's Hospital. Hydromorphone. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2016 [cited 2020 Mar 31]. Available from: https://thewomenspbmg.org.au/</p> <p>Society of Hospital Pharmacists of Australia. Hydromorphone. In:</p>

	<p>Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2017 [cited 2020 Mar 31]. Available from: http://aidh.hcn.com.au</p> <p>Australian Medicines Handbook. Hydromorphone. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2017 [cited 2020 Mar 30]. Available from: https://amhonline.amh.net.au/</p> <p>MIMS Australia. Dilaudid Oral Liquid. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2020 Mar 29]. Available from: https://www.mimsonline.com.au</p> <p>MIMS Australia. Dilaudid Solution for Injection. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2020 Mar 31]. Available from: https://www.mimsonline.com.au</p> <p>MIMS Australia. Dilaudid Tablets. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2016 [cited 2020 Mar 31]. Available from: https://www.mimsonline.com.au</p>
--	--

Keywords:	Hydromorphone, Dilaudid, Journista, Opioid, Analgesia, Pain, Palliative care		
Publishing:	<input checked="" type="checkbox"/> Intranet	<input checked="" type="checkbox"/> Internet	
Document owner:	Chief Pharmacist		
Author / Reviewer:	Pharmacy Department		
Date first issued:	August 2015	Version:	4.0
Last reviewed:	April 2020	Next review date:	March 2023
Endorsed by:	Medicines and Therapeutics Committee	Date:	Aug 2015
Standards Applicable:	NSQHS Standards: 1  Governance, 4  Medication Safety		
<p>Printed or personally saved electronic copies of this document are considered uncontrolled.</p> <p>Access the current version from the WNHS website.</p> <p>For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au</p>			

© Department of Health Western Australia 2020